The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Abstract

In spite of great advances in modern medicine, there are a few effective strategies for the treatment of neurodegenerative diseases characterised by neuron loss or degeneration. This results from complex pathogenesis of the diseases and the limited drug uptake of the brain due to the presence of blood-brain barrier. Nanoparticle-based drug delivery systems are expected to improve the drug utilisation. Polymeric nanoparticles represent promising drug delivery carriers to the brain due to their unique advantages such as good biodegradability and biocompatibility, flexibility in surface modification and nontoxicity. In addition, the delivery of genetic drugs may stop the progression of neurodegenerative diseases at the genetic level and even avoid the irreversible damage in the central nervous system. In this review, an overview of studies on polymer-based nanoparticles for drug delivery to the central nervous system in typical neurodegenerative diseases, especially Alzheimer's diseases and Parkinson's diseases, is described. Meanwhile, their applications in gene delivery in these disorders are discussed. And the challenges and future perspectives for the development of polymeric nanoparticles as drug delivery carriers in neurodegenerative diseases are concluded.

Keywords

drug delivery / gene delivery / nanoparticles / neurodegenerative diseases / polymer

References

[1] L. Agnello and M. Ciaccio, “Neurodegenerative Diseases: From Molecular Basis to Therapy,” International Journal of Molecular Sciences 23, no. 21 (2022): 12854.

[2] C. Ricci, “Study on Genotypes and Phenotypes of Neurodegenerative Diseases,” Genes (Basel) 15 (2024): 786.

[3] J. Bradbury, “Proteolysis Problems Implicated in Neurodegenerative Diseases,” Lancet 357 (2001): 1679.

[4] T. Liu, X. Han, X. Sun, et al., “An Activated Fluorescent Probe to Monitor NO Fluctuation in Parkinson's Disease,” Chinese Chemical Letters (2024): 110170, https://doi.org/10.1016/j.cclet.2024.110170.

[5] C. Cong, W. Liang, C. Zhang, et al., “PAK4 Suppresses Motor Neuron Degeneration in hSOD1(G93A) -Linked Amyotrophic Lateral Sclerosis Cell and Rat Models,” Cell Proliferation 54 (2021): e13003.

[6] M. Bock, S. J. Hong, S. Zhang, et al., “Morphogenetic Designs, and Disease Models in Central Nervous System Organoids,” International Journal of Molecular Sciences 25 (2024): 7750.

[7] Y. Chen, C. Qin, J. Huang, et al., “The Role of Astrocytes in Oxidative Stress of Central Nervous System: A Mixed Blessing,” Cell Proliferation 53 (2020): e12781.

[8] M. Chen, X. Wang, C. Li, et al., “Inducible Motor Neuron Differentiation of Human Induced Pluripotent Stem Cells In Vivo,” Cell Proliferation 55 (2022): e13319.

[9] G. G. Kovacs, “Cellular Reactions of the Central Nervous System,” Handbook of Clinical Neurology 145 (2017): 13-23.

[10] L. Gao, X. Pan, J. H. Zhang, and Y. Xia, “Glial Cells: An Important Switch for the Vascular Function of the Central Nervous System,” Frontiers in Cellular Neuroscience 17 (2023): 1166770.

[11] K. Wang, Y. Wang, L. Wang, et al., “Therapeutic siRNA Targeting C-C Chemokine Receptor 2 Loaded With Tetrahedral Framework Nucleic Acid Alleviates Neuropathic Pain by Regulating Microglial Polarization,” Chinese Chemical Letters (2024): 109868, https://doi.org/10.1016/j.cclet.2024.109868.

[12] A. M. Gorman, “Neuronal Cell Death in Neurodegenerative Diseases: Recurring Themes Around Protein Handling,” Journal of Cellular and Molecular Medicine 12 (2008): 2263-2280.

[13] Y. F. Jiang, Z. Zeng, J. Yao, et al., “Treatment of Alzheimer's Disease With Small-Molecule Photosensitizers,” Chinese Chemical Letters 34 (2023): 107966.

[14] G. Carstens, M. M. Verbeek, U. K. Rohlwink, A. A. Figaji, L. Te Brake, and A. van Laarhoven, “Metabolite Transport Across Central Nervous System Barriers,” Journal of Cerebral Blood Flow and Metabolism 44 (2024): 1063-1077.

[15] W. J. Gardner, “The Barriers of the Central Nervous System,” Clinical Neurosurgery 15 (1968): 80-100.

[16] E. T. MacKenzie, J. McCulloch, M. O'Kean, J. D. Pickard, and A. M. Harper, “Cerebral Circulation and Norepinephrine: Relevance of the Blood-Brain Barrier,” American Journal of Physiology 231 (1976): 483-488.

[17] P. H. Hashimoto, “Blood-Brain Barrier and Cerebrospinal Fluid Circulation,” Kaibogaku Zasshi 67 (1992): 595-605.

[18] Y. L. Fang, Y. Wang, L. Zhu, et al., “A Novel Cartridge for Nucleic Acid Extraction, Amplification and Detection of Infectious Disease Pathogens With the Help of Magnetic Nanoparticles,” Chinese Chemical Letters 34 (2023): 108092.

[19] Z. K. Guo, B. Jin, Y. Fang, et al., “Automated Screening of Primary Cell-Based Aptamers for Targeting and Therapy of Pancreatic Cancer,” Chinese Chemical Letters 35 (2023): 108528.

[20] Y. Liu, T. Li, G. Yang, Y. Deng, X. Mou, and N. He, “A Simple AuNPs-Based Colorimetric Aptasensor for Chlorpyrifos Detection,” Chinese Chemical Letters 33 (2022): 1913-1916.

[21] H. Zhao, E. Su, L. Huang, et al., “Washing-Free Chemiluminescence Immunoassay for Rapid Detection of Cardiac Troponin I in Whole Blood Samples,” Chinese Chemical Letters 33 (2022): 743-746.

[22] W. M. Pardridge, “Biopharmaceutical Drug Targeting to the Brain,” Journal of Drug Targeting 18 (2010): 157-167.

[23] S. Balakrishnan, F. A. Bhat, P. Raja Singh, et al., “Gold Nanoparticle-Conjugated Quercetin Inhibits Epithelial-Mesenchymal Transition, Angiogenesis and Invasiveness via EGFR/VEGFR-2-Mediated Pathway in Breast Cancer,” Cell Proliferation 49 (2016): 678-697.

[24] X. R. Shao, X. Q. Wei, X. Song, et al., “Independent Effect of Polymeric Nanoparticle Zeta Potential/Surface Charge, on Their Cytotoxicity and Affinity to Cells,” Cell Proliferation 48 (2015): 465-474.

[25] G. Tosi, J. T. Duskey, and J. Kreuter, “Nanoparticles as Carriers for Drug Delivery of Macromolecules Across the Blood-Brain Barrier,” Expert Opinion on Drug Delivery 17 (2020): 23-32.

[26] S. Zhang, B. Yang, X. Shen, et al., “AAV-Mediated Gene Therapy Restores Natural Fertility and Improves Physical Function in the Lhcgr-Deficient Mouse Model of Leydig Cell Failure,” Cell Proliferation 57 (2024): e13680.

[27] D. Wang, P. W. L. Tai, and G. Gao, “Adeno-Associated Virus Vector as a Platform for Gene Therapy Delivery,” Nature Reviews. Drug Discovery 18 (2019): 358-378.

[28] M. Ramamoorth and A. Narvekar, “Non Viral Vectors in Gene Therapy-An Overview,” Journal of Clinical and Diagnostic Research 9 (2015): GE01-06.

[29] H. Zu and D. Gao, “Non-Viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects,” AAPS Journal 23 (2021): 78.

[30] T. Patel, J. Zhou, J. M. Piepmeier, and W. M. Saltzman, “Polymeric Nanoparticles for Drug Delivery to the Central Nervous System,” Advanced Drug Delivery Reviews 64 (2012): 701-705.

[31] L. Jin, X. Zeng, M. Liu, Y. Deng, and N. He, “Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-Carriers,” Theranostics 4 (2014): 240-255.

[32] L. Garcia, S. Palma-Florez, V. Espinosa, et al., “Ferulic Acid-Loaded Polymeric Nanoparticles Prepared From Nano-Emulsion Templates Facilitate Internalisation Across the Blood-Brain Barrier in Model Membranes,” Nanoscale 15 (2023): 7929-7944.

[33] T. T. Zhang, W. Li, G. Meng, P. Wang, and W. Liao, “Strategies for Transporting Nanoparticles Across the Blood-Brain Barrier,” Biomaterials Science 4 (2016): 219-229.

[34] C. Conte, G. Longobardi, A. Barbieri, et al., “Non-Covalent Strategies to Functionalize Polymeric Nanoparticles With NGR Peptides for Targeting Breast Cancer,” International Journal of Pharmaceutics 633 (2023): 122618.

[35] A. Vakurov, N. A. Pchelintsev, J. Forde, C. Ó'Fágáin, T. Gibson, and P. Millner, “The Preparation of Size-Controlled Functionalized Polymeric Nanoparticles in Micelles,” Nanotechnology 20 (2009): 295605.

[36] H. Zhou, S. Zhang, F. Lv, et al., “Citrate-Assisted Efficient Local Delivery of Naked Oligonucleotide Into Live Mouse Brain Cells,” Cell Proliferation 52 (2019): e12622.

[37] X. Shao, W. Cui, X. Xie, W. Ma, Y. Zhan, and Y. Lin, “Treatment of Alzheimer's Disease With Framework Nucleic Acids,” Cell Proliferation 53 (2020): e12787.

[38] W. Zhang, A. Mehta, Z. Tong, L. Esser, and N. H. Voelcker, “Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges,” Advanced Science 8 (2021): 2003937.

[39] W. Y. Ong, S. M. Shalini, and L. Costantino, “Nose-To-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders,” Current Medicinal Chemistry 21 (2014): 4247-4256.

[40] S. Virameteekul, A. J. Lees, and R. Bhidayasiri, “Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease,” Movement Disorders 39 (2024): 1922-1937.

[41] Y. Gao, C. Yang, L. Wang, et al., “Comparable Intestinal and Hepatic First-Pass Effect of YL-IPA08 on the Bioavailability and Effective Brain Exposure, a Rapid Anti-PTSD and Anti-Depression Compound,” Frontiers in Pharmacology 11 (2020): 588127.

[42] P. Wang, Y. Wang, P. Li, et al., “Oral Delivery of Polyester Nanoparticles for Brain-Targeting: Challenges and Opportunities,” Chinese Chemical Letters 34 (2023): 107691.

[43] C. M. Hamadani, G. S. Dasanayake, M. E. Gorniak, et al., “Development of Ionic Liquid-Coated PLGA Nanoparticles for Applications in Intravenous Drug Delivery,” Nature Protocols 18 (2023): 2509-2557.

[44] F. Wang, L. Qi, Z. Zhang, et al., “The Mechanism and Latest Research Progress of Blood-Brain Barrier Breakthrough,” Biomedicine 12 (2024): 2302.

[45] M. Agrawal, Ajazuddin, D. K. Tripathi, et al., “Recent Advancements in Liposomes Targeting Strategies to Cross Blood-Brain Barrier (BBB) for the Treatment of Alzheimer's Disease,” Journal of Controlled Release 260 (2017): 61-77.

[46] I. Brasnjevic, H. W. Steinbusch, C. Schmitz, P. Martinez-Martinez, and European NanoBioPharmaceutics Research, I, “Delivery of Peptide and Protein Drugs Over the Blood-Brain Barrier,” Progress in Neurobiology 87 (2009): 212-251.

[47] B. Jafari, M. M. Pourseif, J. Barar, M. A. Rafi, and Y. Omidi, “Peptide-Mediated Drug Delivery Across the Blood-Brain Barrier for Targeting Brain Tumors,” Expert Opinion on Drug Delivery 16 (2019): 583-605.

[48] M. Ayer, M. Schuster, I. Gruber, et al., “T Cell-Mediated Transport of Polymer Nanoparticles Across the Blood-Brain Barrier,” Advanced Healthcare Materials 10 (2021): e2001375.

[49] A. Cox, D. Vinciguerra, F. Re, et al., “Protein-Functionalized Nanoparticles Derived From End-Functional Polymers and Polymer Prodrugs for Crossing the Blood-Brain Barrier,” European Journal of Pharmaceutics and Biopharmaceutics 142 (2019): 70-82.

[50] Q. Lu, X. Cai, X. Zhang, et al., “Synthetic Polymer Nanoparticles Functionalized With Different Ligands for Receptor-Mediated Transcytosis Across Blood-Brain Barrier,” ACS Applied Bio Materials 1 (2018): 1687-1694.

[51] L. Guerrini, R. A. Alvarez-Puebla, and N. Pazos-Perez, “Surface Modifications of Nanoparticles for Stability in Biological Fluids,” Materials (Basel) 11 (2018): 1154.

[52] D. Pozzi, V. Colapicchioni, G. Caracciolo, et al., “Effect of Polyethyleneglycol (PEG) Chain Length on the Bio-Nano-Interactions Between PEGylated Lipid Nanoparticles and Biological Fluids: From Nanostructure to Uptake in Cancer Cells,” Nanoscale 6 (2014): 2782-2792.

[53] R. Moreira, C. Nobrega, L. P. de Almeida, and L. Mendonca, “Brain-Targeted Drug Delivery-Nanovesicles Directed to Specific Brain Cells by Brain-Targeting Ligands,” Journal of Nanobiotechnology 22 (2024): 260.

[54] A. Kobo-Greenhut, H. Frankenthal, A. Darawsha, et al., “A Non-Invasive Direct Nose to Brain Drug Delivery Platform vs. Invasive Brain Delivery Approach: Patient-Centered Care Impact Analysis,” Drug Delivery 29 (2022): 1754-1763.

[55] N. Montegiove, E. Calzoni, C. Emiliani, and A. Cesaretti, “Biopolymer Nanoparticles for Nose-To-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases,” Journal of Functional Biomaterials 13 (2022): 125.

[56] C. V. Pardeshi and V. S. Belgamwar, “Direct Nose to Brain Drug Delivery via Integrated Nerve Pathways Bypassing the Blood-Brain Barrier: An Excellent Platform for Brain Targeting,” Expert Opinion on Drug Delivery 10 (2013): 957-972.

[57] P. G. Djupesland, J. C. Messina, and R. A. Mahmoud, “The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview,” Therapeutic Delivery 5 (2014): 709-733.

[58] A. R. Khan, M. Liu, M. W. Khan, and G. Zhai, “Progress in Brain Targeting Drug Delivery System by Nasal Route,” Journal of Controlled Release 268 (2017): 364-389.

[59] H. Akel, R. Ismail, and I. Csoka, “Progress and Perspectives of Brain-Targeting Lipid-Based Nanosystems via the Nasal Route in Alzheimer's Disease,” European Journal of Pharmaceutics and Biopharmaceutics 148 (2020): 38-53.

[60] M. van Woensel, N. Wauthoz, R. Rosière, et al., “Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?,” Cancers (Basel) 5 (2013): 1020-1048.

[61] Y. Chen, C. Zhang, Y. Huang, et al., “Intranasal Drug Delivery: The Interaction Between Nanoparticles and the Nose-To-Brain Pathway,” Advanced Drug Delivery Reviews 207 (2024): 115196.

[62] M. Agrawal, S. Saraf, S. Saraf, et al., “Nose-To-Brain Drug Delivery: An Update on Clinical Challenges and Progress Towards Approval of Anti-Alzheimer Drugs,” Journal of Controlled Release 281 (2018): 139-177.

[63] C. Feng, C. Zhang, X. Shao, et al., “Enhancement of Nose-To-Brain Delivery of Basic Fibroblast Growth Factor for Improving Rat Memory Impairments Induced by Co-Injection of Beta-Amyloid and Ibotenic Acid Into the Bilateral Hippocampus,” International Journal of Pharmaceutics 423 (2012): 226-234.

[64] R. G. Madane and H. S. Mahajan, “Curcumin-Loaded Nanostructured Lipid Carriers (NLCs) for Nasal Administration: Design, Characterization, and In Vivo Study,” Drug Delivery 23 (2016): 1326-1334.

[65] A. Mistry, S. Z. Glud, J. Kjems, et al., “Effect of Physicochemical Properties on Intranasal Nanoparticle Transit Into Murine Olfactory Epithelium,” Journal of Drug Targeting 17 (2009): 543-552.

[66] A. Mistry, S. Stolnik, and L. Illum, “Nanoparticles for Direct Nose-To-Brain Delivery of Drugs,” International Journal of Pharmaceutics 379 (2009): 146-157.

[67] O. Gartziandia, S. P. Egusquiaguirre, J. Bianco, et al., “Nanoparticle Transport Across In Vitro Olfactory Cell Monolayers,” International Journal of Pharmaceutics 499 (2016): 81-89.

[68] L. Illum, “Nanoparticulate Systems for Nasal Delivery of Drugs: A Real Improvement Over Simple Systems?,” Journal of Pharmaceutical Sciences 96 (2007): 473-483.

[69] S. Md, N. A. Alhakamy, H. M. Aldawsari, and H. Z. Asfour, “Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-To-Brain Delivery,” Brain Sciences 9 (2019): 275.

[70] P. Scheltens, B. de Strooper, M. Kivipelto, et al., “Alzheimer's Disease,” Lancet 397 (2021): 1577-1590.

[71] R. Barnett, “Alzheimer's Disease,” Lancet 393 (2019): 1589.

[72] R. Anand, K. D. Gill, and A. A. Mahdi, “Therapeutics of Alzheimer's Disease: Past, Present and Future,” Neuropharmacology 76 (2014): 27-50.

[73] C. P. Ferri, M. Prince, C. Brayne, et al., “Global Prevalence of Dementia: A Delphi Consensus Study,” Lancet 366 (2005): 2112-2117.

[74] D. S. Himmelstein, S. M. Ward, J. K. Lancia, K. R. Patterson, and L. I. Binder, “Tau as a Therapeutic Target in Neurodegenerative Disease,” Pharmacology & Therapeutics 136 (2012): 8-22.

[75] M. Oz, D. E. Lorke, K. H. Yang, and G. Petroianu, “On the Interaction of Beta-Amyloid Peptides and Alpha7-Nicotinic Acetylcholine Receptors in Alzheimer's Disease,” Current Alzheimer Research 10 (2013): 618-630.

[76] E. Manek, F. Darvas, and G. A. Petroianu, “Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer's Disease,” Molecules 25 (2020): 4866.

[77] X. Dong, G. Pei, Z. Yang, and S. Huang, “Flavonoid Chrysin Activates Both TrkB and FGFR1 Receptors While Upregulates Their Endogenous Ligands Such as Brain Derived Neurotrophic Factor to Promote Human Neurogenesis,” Cell Proliferation 58, no. 1 (2024): e13732.

[78] G. Karthivashan, P. Ganesan, S. Y. Park, J. S. Kim, and D. K. Choi, “Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Ageing Alzheimer's Disease,” Drug Delivery 25 (2018): 307-320.

[79] I. Reimold, D. Domke, J. Bender, C. A. Seyfried, H. E. Radunz, and G. Fricker, “Delivery of Nanoparticles to the Brain Detected by Fluorescence Microscopy,” European Journal of Pharmaceutics and Biopharmaceutics 70 (2008): 627-632.

[80] R. Awad, A. Avital, and A. Sosnik, “Polymeric Nanocarriers for Nose-To-Brain Drug Delivery in Neurodegenerative Diseases and Neurodevelopmental Disorders,” Acta Pharmaceutica Sinica B 13 (2023): 1866-1886.

[81] L. La Barbera, E. Mauri, M. D'Amelio, and M. Gori, “Functionalization Strategies of Polymeric Nanoparticles for Drug Delivery in Alzheimer's Disease: Current Trends and Future Perspectives,” Frontiers in Neuroscience 16 (2022): 939855.

[82] A. S. Hanafy, R. M. Farid, M. W. Helmy, and S. S. ElGamal, “Pharmacological, Toxicological and Neuronal Localization Assessment of Galantamine/Chitosan Complex Nanoparticles in Rats: Future Potential Contribution in Alzheimer's Disease Management,” Drug Delivery 23 (2016): 3111-3122.

[83] L. S. Kandil, R. M. Farid, S. S. ElGamal, and A. S. Hanafy, “Intranasal Galantamine/Chitosan Complex Nanoparticles Elicit Neuroprotection Potentials in Rat Brains via Antioxidant Effect,” Drug Development and Industrial Pharmacy 47 (2021): 735-740.

[84] Sunena, S. K. Singh, and D. N. Mishra, “Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-Vivo Pharmacodynamic and Biochemical Study in Mice,” Current Drug Delivery 16 (2019): 51-58.

[85] L. Yang, Y. Wang, Z. Li, X. Wu, J. Mei, and G. Zheng, “Brain Targeted Peptide-Functionalized Chitosan Nanoparticles for Resveratrol Delivery: Impact on Insulin Resistance and Gut Microbiota in Obesity-Related Alzheimer's Disease,” Carbohydrate Polymers 310 (2023): 120714.

[86] B. Anand, Q. Wu, M. Nakhaei-Nejad, et al., “Significance of Native PLGA Nanoparticles in the Treatment of Alzheimer's Disease Pathology,” Bioactive Materials 17 (2022): 506-525.

[87] M. Yang, L. Jin, Z. Wu, et al., “PLGA-PEG Nanoparticles Facilitate In Vivo Anti-Alzheimer's Effects of Fucoxanthin, a Marine Carotenoid Derived From Edible Brown Algae,” Journal of Agricultural and Food Chemistry 69 (2021): 9764-9777.

[88] S. R. Saleh, A. Abd-Elmegied, S. Aly Madhy, et al., “Brain-Targeted Tet-1 Peptide-PLGA Nanoparticles for Berberine Delivery Against STZ-Induced Alzheimer's Disease in a Rat Model: Alleviation of Hippocampal Synaptic Dysfunction, Tau Pathology, and Amyloidogenesis,” International Journal of Pharmaceutics 658 (2024): 124218.

[89] A. K. Mahanta, B. Chaulagain, R. Trivedi, and J. Singh, “Mannose-Functionalized Chitosan-Coated PLGA Nanoparticles for Brain-Targeted Codelivery of CBD and BDNF for the Treatment of Alzheimer's Disease,” ACS Chemical Neuroscience 15 (2024): 4021-4032.

[90] L. Yao, X. Gu, Q. Song, et al., “Nanoformulated Alpha-Mangostin Ameliorates Alzheimer's Disease Neuropathology by Elevating LDLR Expression and Accelerating Amyloid-Beta Clearance,” Journal of Controlled Release 226 (2016): 1-14.

[91] Q. Guo, Y. Li, S. Xu, et al., “Brain-Neuron Targeted Nanoparticles for Peptide Synergy Therapy at Dual-Target of Alzheimer's Disease,” Journal of Controlled Release 355 (2023): 604-621.

[92] R. Zhou, L. Zhu, Z. Zeng, et al., “Targeted Brain Delivery of RVG29-Modified Rifampicin-Loaded Nanoparticles for Alzheimer's Disease Treatment and Diagnosis,” Bioengineering & Translational Medicine 7 (2022): e10395.

[93] D. E. Igartua, C. S. Martinez, V. A. S. Del, and M. J. Prieto, “Combined Therapy for Alzheimer's Disease: Tacrine and PAMAM Dendrimers Co-Administration Reduces the Side Effects of the Drug Without Modifying Its Activity,” AAPS PharmSciTech 21 (2020): 110.

[94] J. Gu, C. Yan, S. Yin, et al., “Erythrocyte Membrane-Coated Nanocarriers Modified by TGN for Alzheimer's Disease,” Journal of Controlled Release 366 (2024): 448-459.

[95] H. Mohamadpour, A. Azadi, K. Rostamizadeh, S. Andalib, M. R. Saghatchi Zanjani, and M. Hamidi, “Preparation, Optimization, and Evaluation of Methoxy Poly(Ethylene Glycol)-Co-Poly(Epsilon-Caprolactone) Nanoparticles Loaded by Rivastigmine for Brain Delivery,” ACS Chemical Neuroscience 11 (2020): 783-795.

[96] T. K. Dash and V. B. Konkimalla, “Polymeric Modification and Its Implication in Drug Delivery: Poly-Epsilon-Caprolactone (PCL) as a Model Polymer,” Molecular Pharmaceutics 9 (2012): 2365-2379.

[97] T. Kanazawa, H. Taki, and H. Okada, “Nose-To-Brain Drug Delivery System With Ligand/Cell-Penetrating Peptide-Modified Polymeric Nano-Micelles for Intracerebral Gliomas,” European Journal of Pharmaceutics and Biopharmaceutics 152 (2020): 85-94.

[98] J. Wang, J. Fu, W. Sun, X. Yin, K. Lv, and J. Zhang, “Functionalized PEG-PLA Nanoparticles for Brain Targeted Delivery of Ketoconazole Contribute to Pregnane X Receptor Overexpressing in Drug-Resistant Epilepsy,” Epilepsy Research 186 (2022): 107000.

[99] D. Georgieva, D. Nikolova, E. Vassileva, and B. Kostova, “Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer's Disease Therapy,” Pharmaceutics 15 (2023): 829.

[100] L. J. Scott and K. L. Goa, “Galantamine: A Review of Its Use in Alzheimer's Disease,” Drugs 60 (2000): 1095-1122.

[101] C. Grinan-Ferre, A. Bellver-Sanchis, V. Izquierdo, et al., “The Pleiotropic Neuroprotective Effects of Resveratrol in Cognitive Decline and Alzheimer's Disease Pathology: From Antioxidant to Epigenetic Therapy,” Ageing Research Reviews 67 (2021): 101271.

[102] N. Oliyaei, M. Moosavi-Nasab, N. Tanideh, and A. Iraji, “Multiple Roles of Fucoxanthin and Astaxanthin Against Alzheimer's Disease: Their Pharmacological Potential and Therapeutic Insights,” Brain Research Bulletin 193 (2023): 11-21.

[103] J. Y. Liu, Y. Dai, Y. X. He, and L. Lin, “Effect of Berberine on Cognitive Function and Beta-Amyloid Precursor Protein in Alzheimer's Disease Models: A Systematic Review and Meta-Analysis,” Frontiers in Pharmacology 14 (2023): 1301102.

[104] C. Sun, S. Dong, W. Chen, J. Li, E. Luo, and J. Ji, “Berberine Alleviates Alzheimer's Disease by Regulating the Gut Microenvironment, Restoring the Gut Barrier and Brain-Gut Axis Balance,” Phytomedicine 129 (2024): 155624.

[105] J. P. Hickey, A. E. Collins, M. L. Nelson, H. Chen, and B. E. Kalisch, “Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease,” Current Issues in Molecular Biology 46 (2024): 4379-4402.

[106] B. L. Marques and A. C. Campos, “Cannabidiol and Alzheimer's Disease,” International Review of Neurobiology 177 (2024): 121-134.

[107] M. Amidfar, M. L. Garcez, G. Askari, et al., “Role of BDNF Signaling in the Neuroprotective and Memory-Enhancing Effects of Flavonoids in Alzheimer's Disease,” CNS & Neurological Disorders Drug Targets 23 (2024): 984-995.

[108] M. Banerjee and R. R. Shenoy, “Emphasizing Roles of BDNF Promoters and Inducers in Alzheimer's Disease for Improving Impaired Cognition and Memory,” Journal of Basic and Clinical Physiology and Pharmacology 34 (2023): 125-136.

[109] I. Zota, K. Chanoumidou, A. Gravanis, and I. Charalampopoulos, “Stimulating Myelin Restoration With BDNF: A Promising Therapeutic Approach for Alzheimer's Disease,” Frontiers in Cellular Neuroscience 18 (2024): 1422130.

[110] H. C. Shin, H. Cho, T. C. Lai, K. R. Kozak, J. M. Kolesar, and G. S. Kwon, “Pharmacokinetic Study of 3-In-1 Poly(Ethylene Glycol)-Block-Poly(D, L-Lactic Acid) Micelles Carrying Paclitaxel, 17-Allylamino-17-Demethoxygeldanamycin, and Rapamycin,” Journal of Controlled Release 163 (2012): 93-99.

[111] Y. Tang, J. Gao, T. Wang, et al., “The Effect of Drug Loading and Multiple Administration on the Protein Corona Formation and Brain Delivery Property of PEG-PLA Nanoparticles,” Acta Pharmaceutica Sinica B 12 (2022): 2043-2056.

[112] B. Le Droumaguet, J. Nicolas, D. Brambilla, et al., “Versatile and Efficient Targeting Using a Single Nanoparticulate Platform: Application to Cancer and Alzheimer's Disease,” ACS Nano 6 (2012): 5866-5879.

[113] R. R. Huang, L. He, L. Jin, Z. Li, N. He, and W. Miao, “Recent Advancements in DNA Nanotechnology-Enabled Extracellular Vesicles Detection and Diagnosis:A Mini Review,” Chinese Chemical Letters 34 (2023): 107926.

[114] M. Huang, R. Cheng, S. Wen, et al., “Ultrasensitive Detection of microRNA-21 in Human Serum Based on the Confinement Effect Enhanced Chemical Etching of Gold Nanorods,” Chinese Chemical Letters 35 (2024): 109379.

[115] N. Fu, J. Liao, S. Lin, et al., “PCL-PEG-PCL Film Promotes Cartilage Regeneration In Vivo,” Cell Proliferation 49 (2016): 729-739.

[116] W. Ni, S. Lin, S. Bian, et al., “Biological Testing of Chitosan-Collagen-Based Porous Scaffolds Loaded With PLGA/Triamcinolone Microspheres for Ameliorating Endoscopic Dissection-Related Stenosis in Oesophagus,” Cell Proliferation 54 (2021): e13004.

[117] Y. Lee, M. Kim, M. Lee, et al., “Mitochondrial Genome Mutations and Neuronal Dysfunction of Induced Pluripotent Stem Cells Derived From Patients With Alzheimer's Disease,” Cell Proliferation 55 (2022): e13274.

[118] X. Xia, X. He, T. Zhao, et al., “Inhibiting mtDNA-STING-NLRP3/IL-1beta Axis-Mediated Neutrophil Infiltration Protects Neurons in Alzheimer's Disease,” Cell Proliferation 57 (2024): e13529.

[119] B. De Strooper and E. Karran, “The Cellular Phase of Alzheimer's Disease,” Cell 164 (2016): 603-615.

[120] H. J. Shin, I. S. Kim, S. G. Choi, et al., “Rejuvenating Aged Microglia by p16(ink4a)-siRNA-Loaded Nanoparticles Increases Amyloid-Beta Clearance in Animal Models of Alzheimer's Disease,” Molecular Neurodegeneration 19 (2024): 25.

[121] H. Park, J. Oh, G. Shim, et al., “In Vivo Neuronal Gene Editing via CRISPR-Cas9 Amphiphilic Nanocomplexes Alleviates Deficits in Mouse Models of Alzheimer's Disease,” Nature Neuroscience 22 (2019): 524-528.

[122] J. Li, H. Peng, W. Zhang, et al., “Enhanced Nose-To-Brain Delivery of Combined Small Interfering RNAs Using Lesion-Recognizing Nanoparticles for the Synergistic Therapy of Alzheimer's Disease,” ACS Applied Materials & Interfaces 15 (2023): 53177-53188.

[123] L. L. Israel, T. Sun, O. Braubach, et al., “Beta-Amyloid Targeting Nanodrug for Neuron-Specific Delivery of Nucleic Acids in Alzheimer's Disease Mouse Models,” Journal of Controlled Release 361 (2023): 636-658.

[124] Collaborators, G.B.D.N, “Global, Regional, and National Burden of Neurological Disorders, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016,” Lancet Neurology 18 (2019): 459-480.

[125] E. R. Dorsey, T. Sherer, M. S. Okun, and B. R. Bloem, “The Emerging Evidence of the Parkinson Pandemic,” Journal of Parkinson's Disease 8 (2018): S3-S8.

[126] P. M. Antony, N. J. Diederich, R. Kruger, and R. Balling, “The Hallmarks of Parkinson's Disease,” FEBS Journal 280 (2013): 5981-5993.

[127] I. Frigerio, M. A. Laansma, C. P. Lin, et al., “Neurofilament Light Chain Is Increased in the Parahippocampal Cortex and Associates With Pathological Hallmarks in Parkinson's Disease Dementia,” Translational Neurodegeneration 12 (2023): 3.

[128] N. Hattori, M. Funayama, Y. Imai, and T. Hatano, “Pathogenesis of Parkinson's Disease: From Hints From Monogenic Familial PD to Biomarkers,” Journal of Neural Transmission (Vienna) 131 (2024): 709-719.

[129] H. R. Morris, M. G. Spillantini, C. M. Sue, and C. H. Williams-Gray, “The Pathogenesis of Parkinson's Disease,” Lancet 403 (2024): 293-304.

[130] Y. Saitoh and K. Takahashi, “Current Pharmacological Treatment for Parkinson's Disease,” Brain and Nerve 75 (2023): 441-449.

[131] I. Zahoor, A. Shafi, and E. Haq, “Pharmacological Treatment of Parkinson's Disease,” in Parkinson's Disease: Pathogenesis and Clinical Aspects, eds. T. B. Stoker and J. C. Greenland (Brisbane, Australia: Codon Publications, 2018).

[132] W. Dauer and S. Przedborski, “Parkinson's Disease: Mechanisms and Models,” Neuron 39 (2003): 889-909.

[133] C. Raza, R. Anjum, and N. U. A. Shakeel, “Parkinson's Disease: Mechanisms, Translational Models and Management Strategies,” Life Sciences 226 (2019): 77-90.

[134] I. N. Khan, S. Navaid, W. Waqar, et al., “Chitosan-Based Polymeric Nanoparticles as an Efficient Gene Delivery System to Cross Blood Brain Barrier: In Vitro and In Vivo Evaluations,” Pharmaceuticals (Basel) 17 (2024): 169.

[135] A. Trapani, E. de Giglio, D. Cafagna, et al., “Characterization and Evaluation of Chitosan Nanoparticles for Dopamine Brain Delivery,” International Journal of Pharmaceutics 419 (2011): 296-307.

[136] R. Raj, S. Wairkar, V. Sridhar, and R. Gaud, “Pramipexole Dihydrochloride Loaded Chitosan Nanoparticles for Nose to Brain Delivery: Development, Characterization and In Vivo Anti-Parkinson Activity,” International Journal of Biological Macromolecules 109 (2018): 27-35.

[137] S. K. Bhattamisra, A. T. Shak, L. W. Xi, et al., “Nose to Brain Delivery of Rotigotine Loaded Chitosan Nanoparticles in Human SH-SY5Y Neuroblastoma Cells and Animal Model of Parkinson's Disease,” International Journal of Pharmaceutics 579 (2020): 119148.

[138] V. Sridhar, R. Gaud, A. Bajaj, and S. Wairkar, “Pharmacokinetics and Pharmacodynamics of Intranasally Administered Selegiline Nanoparticles With Improved Brain Delivery in Parkinson's Disease,” Nanomedicine 14 (2018): 2609-2618.

[139] M. Pinto, V. Silva, S. Barreiro, et al., “Brain Drug Delivery and Neurodegenerative Diseases: Polymeric PLGA-Based Nanoparticles as a Forefront Platform,” Ageing Research Reviews 79 (2022): 101658.

[140] R. Pahuja, K. Seth, A. Shukla, et al., “Trans-Blood Brain Barrier Delivery of Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats,” ACS Nano 9 (2015): 4850-4871.

[141] R. Pahuja, K. Seth, A. Shukla, et al., “Correction to Trans-Blood Brain Barrier Delivery of Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats,” ACS Nano 13 (2019): 8490.

[142] D. E. Owens and N. A. Peppas, “Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles,” International Journal of Pharmaceutics 307 (2006): 93-102.

[143] Y. Zhao, S. Xiong, P. Liu, et al., “Polymeric Nanoparticles-Based Brain Delivery With Improved Therapeutic Efficacy of Ginkgolide B in Parkinson's Disease,” International Journal of Nanomedicine 15 (2020): 10453-10467.

[144] Y. Liu, P. Wang, C. Sun, et al., “Bioadhesion and Enhanced Bioavailability by Wheat Germ Agglutinin-Grafted Lipid Nanoparticles for Oral Delivery of Poorly Water-Soluble Drug Bufalin,” International Journal of Pharmaceutics 419 (2011): 260-265.

[145] S. Arisoy, O. Sayiner, T. Comoglu, D. Onal, O. Atalay, and B. Pehlivanoglu, “In Vitro and In Vivo Evaluation of Levodopa-Loaded Nanoparticles for Nose to Brain Delivery,” Pharmaceutical Development and Technology 25 (2020): 735-747.

[146] V. Monge-Fuentes, A. Biolchi Mayer, M. R. Lima, et al., “Dopamine-Loaded Nanoparticle Systems Circumvent the Blood-Brain Barrier Restoring Motor Function in Mouse Model for Parkinson's Disease,” Scientific Reports 11 (2021): 15185.

[147] S. Penco, S. Scarfi, M. Giovine, et al., “Identification of an Import Signal for, and the Nuclear Localization of, Human Lactoferrin,” Biotechnology and Applied Biochemistry 34 (2001): 151-159.

[148] C. Zhao, X. Zhu, H. Yang, et al., “Lactoferrin/CD133 Antibody Conjugated Nanostructured Lipid Carriers for Dual Targeting of Blood-Brain-Barrier and Glioblastoma Stem Cells,” Biomedical Materials 19 (2024): 055041.

[149] C. Bi, A. Wang, Y. Chu, et al., “Intranasal Delivery of Rotigotine to the Brain With Lactoferrin-Modified PEG-PLGA Nanoparticles for Parkinson's Disease Treatment,” International Journal of Nanomedicine 11 (2016): 6547-6559.

[150] S. Tang, A. Wang, X. Yan, et al., “Brain-Targeted Intranasal Delivery of Dopamine With Borneol and Lactoferrin Co-Modified Nanoparticles for Treating Parkinson's Disease,” Drug Delivery 26 (2019): 700-707.

[151] C. Helmschrodt, S. Höbel, S. Schöniger, et al., “Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce Alpha-Synuclein Expression in a Model of Parkinson's Disease,” Molecular Therapy - Nucleic Acids 9 (2017): 57-68.

[152] J. Lee, J. Jung, Y. J. Kim, E. Lee, and J. S. Choi, “Gene Delivery of PAMAM Dendrimer Conjugated With the Nuclear Localization Signal Peptide Originated From Fibroblast Growth Factor 3,” International Journal of Pharmaceutics 459 (2014): 10-18.

[153] R. Huang, L. Han, J. Li, et al., “Neuroprotection in a 6-Hydroxydopamine-Lesioned Parkinson Model Using Lactoferrin-Modified Nanoparticles,” Journal of Gene Medicine 11 (2009): 754-763.

[154] C. Saraiva, L. Ferreira, and L. Bernardino, “Traceable microRNA-124 Loaded Nanoparticles as a New Promising Therapeutic Tool for Parkinson's Disease,” Neurogenesis 3 (2016): e1256855.

[155] Z. Irfan, S. Khanam, V. Karmakar, et al., “Pathogenesis of Huntington's Disease: An Emphasis on Molecular Pathways and Prevention by Natural Remedies,” Brain Sciences 12 (2022): 1389.

[156] H. Tong, T. Yang, S. Xu, et al., “Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies,” International Journal of Molecular Sciences 25 (2024): 3845.

[157] V. Sava, O. Fihurka, A. Khvorova, and J. Sanchez-Ramos, “Enriched Chitosan Nanoparticles Loaded With siRNA Are Effective in Lowering Huntington's Disease Gene Expression Following Intranasal Administration,” Nanomedicine 24 (2020): 102119.

[158] D. Belletti, A. M. Grabrucker, F. Pederzoli, et al., “Hybrid Nanoparticles as a New Technological Approach to Enhance the Delivery of Cholesterol Into the Brain,” International Journal of Pharmaceutics 543 (2018): 300-310.

[159] Y. Lu, J. T. W. Wang, N. Li, et al., “Intranasal Administration of Edaravone Nanoparticles Improves Its Stability and Brain Bioavailability,” Journal of Controlled Release 359 (2023): 257-267.

[160] C. Tallon, A. Sharma, Z. Zhang, et al., “Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis,” Neurotherapeutics 19 (2022): 274-288.

[161] M. B. Violatto, L. Pasetto, E. Casarin, et al., “Development of a Nanoparticle-Based Approach for the Blood-Brain Barrier Passage in a Murine Model of Amyotrophic Lateral Sclerosis,” Cells 11 (2022): 4003.

[162] X. Zhao, L. Sun, J. Wang, et al., “Nose to Brain Delivery of Astragaloside IV by Beta-Asarone Modified Chitosan Nanoparticles for Multiple Sclerosis Therapy,” International Journal of Pharmaceutics 644 (2023): 123351.

[163] Z. Hunter, D. P. McCarthy, W. T. Yap, et al., “A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease,” ACS Nano 8 (2014): 2148-2160.

[164] M. Dai, N. Yang, K. Xu, et al., “Discovering Human Cell-Compatible Gene Therapy Virus Variants via Optimized Screening in Mouse Models,” Cell Proliferation 57 (2024): e13565.

[165] S. Hua, M. B. C. de Matos, J. M. Metselaar, and G. Storm, “Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization,” Frontiers in Pharmacology 9 (2018): 790.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.